Range Impact Announces Expansion of Investment in its Fola Mine Complex with Acquisition of Two Mining Permits and Two Coal Leases
CLEVELAND, OHIO, July 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB:…
Indie Fashion Brand IshqMe Pays Tribute to Nature with its New Enchanting Garden Collection
CHENNAI, India, July 3, 2025 /PRNewswire/ -- Emerging fashion powerhouse, IshqMe launches…
reAlpha Enhances Mortgage Operations with AI-Powered Loan Officer Assistant
DUBLIN, Ohio, July 02, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq:…
FIS continues commitment to Para events safety and accessibility with annual site visits
Jul 02, 2025 - Every year, generally towards the back end of the…
Genesis AI Emerges From Stealth with $105M to Build Universal Robotics Foundation Model and Horizontal Platform for General-Purpose Physical AI
With funding co-led by Eclipse and Khosla Ventures, Genesis will develop breakthrough…
Vantage Dominates Online Money Awards 2025 with Wins for Best Multi-Asset Broker & Customer Service
PORT VILA, Vanuatu, July 1, 2025 /PRNewswire/ -- The globally recognised Vantage brand…
DeTect and Hanseo University Deepen Collaboration with Radar Deployment at the Taean Flight Education Center
TAEAN, South Korea, July 2, 2025 /PRNewswire/ -- DeTect, Inc., a global leader…
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward…
Compass Mining Energizes New 4.5 MW Site in Iowa in Partnership with DIGTB
The new site strengthens the company's ability to help its hosting customers…
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
July 01, 2025 09:00 ET | Source: Inmagene Biopharmaceuticals The ADAPTIVE Phase…
